Prostate-specific antigen and prostate cancer

Area of Science:

• Urology
• Oncology
• Biochemistry

Background:

• Serum prostate-specific antigen (PSA) is a key biomarker for prostate health.
• PSA levels can be elevated in both prostate cancer and benign prostatic conditions.
• Early detection of prostate cancer is crucial for effective treatment.

Purpose of the Study:

• To evaluate the utility of serum PSA measurements in diagnosing prostate cancer.
• To explore methods for differentiating prostate cancer from benign prostatic hypertrophy (BPH).
• To assess the role of PSA in monitoring prostate cancer treatment and surveillance.

Main Methods:

• Analysis of serum PSA levels in patients with lower urinary tract symptoms and asymptomatic individuals.
• Correlation of PSA levels with prostatic malignancy and benign prostatic disease.
• Utilizing serial PSA measurements, prostatic volume correction, and free PSA (fPSA) fraction analysis.
• Monitoring PSA trends during and after prostate cancer treatment.

Main Results:

• Elevated serum PSA is observed in approximately 60% of early prostate cancer cases and 20% of benign prostatic disease cases.
• Slightly elevated PSA levels can be challenging to interpret; fPSA measurement aids differentiation.
• Serial PSA measurements and fPSA levels are valuable for distinguishing prostate cancer from BPH.
• Serial PSA monitoring is effective for assessing treatment response and post-treatment surveillance.

Conclusions:

• Serum PSA measurement is a valuable tool for prostate cancer screening and investigation.
• Free PSA fraction analysis significantly improves the diagnostic accuracy in cases of equivocal PSA levels.
• PSA monitoring is essential for managing prostate cancer patients throughout their treatment journey.